Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Amgen facilities approved

Executive Summary

Two Amgen manufacturing facilities have been approved by FDA, one in West Greenwich, R.I. for production of the inflammation biologic Enbrel (etanercept) and another in Juncos, Puerto Rico, licensed for commercial bulk manufacturing of Neupogen (filgrastim) and Neulasta (pegfilgrastim), the company said. Amgen invested more than $1.1 bil. in the Rhode Island facility, originally licensed in 2002, to expand the campus by 500,000 sq. ft. The company is investing $1.2 bil. to expand the Puerto Rico site, which became operational in 1993. A second facility there will be used for the production of Epogen (epoetin alfa) and Aranesp (darbepoetin alfa)...





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts